The creation of new proteins and peptides for use with CRISPR represents the next stage in the evolution of this technology.
Category: bioengineering – Page 89
Janice Chen, Ph.D., one of Olympic gold medalist Nathan Chen’s siblings, is on a mission to build a $100 billion biotech company.
In 2018, she co-founded Mammoth Biosciences with Trevor Martin, Lucas Harrington and Jennifer Doudna 0, who won the Nobel Prize in Chemistry two years later for her pioneering work in CRISPR gene editing. Doudna also served as Chen’s mentor while she pursued her doctorate degree in molecular and cell biology at the University of California at Berkeley.
Mammoth is built on Chen’s work as a graduate student researcher in Doudna’s lab. Since the dawn of COVID-19 in 2020, the startup has seen accelerated growth as it snagged $100 million in multiple contracts and government grants.
R/IntelligenceSupernova — dedicated to techno-optimists, singularitarians, transhumanist thinkers, cosmists, futurists, AI researchers, cyberneticists, crypto enthusiasts, VR creators, artists, philosophers of mind. Accelerating now towards the Cybernetic Singularity with unprecedented advances in AI & Cybernetics, VR, Biotechnology, Nanotechnology, Bionics, Genetic Engineering, Optogenetics, Neuroengineering, Robotics, and other IT fields.
Join now: https://www.reddit.com/r/IntelligenceSupernova.
#Subreddit #IntelligenceSupernova
(Inside Science) — An enzyme in the bacterium E. coli made more errors copying synthetic DNA when exposed to zero gravity than the same enzyme did in normal gravity, a recent study finds.
The paper raises the possibility that some enzymes work differently in space compared to on Earth. “It gives us an idea that enzymes, like polymerases or others that are involved in maintaining the integrity of our DNA, may be influenced by spaceflight,” said Susan Bailey, a radiation cancer biologist at Colorado State University in Fort Collins who has studied DNA damage caused by space radiation and did not contribute to the new paper.
Aaron Rosenstein, lead author of the paper and a bioengineering graduate student at the University of Toronto, said the finding “warrants further investigation into other enzymes that are involved in crucial pathways that are inherent to life and survival.”
Synopsis: No sentient being in the evolutionary history of life has enjoyed good health as defined by the World Health Organization. The founding constitution of the World Health Organization commits the international community to a daringly ambitious conception of health: “a state of complete physical, mental and social wellbeing”. Health as so conceived is inconsistent with evolution via natural selection. Lifelong good health is inconsistent with a Darwinian genome. Indeed, the vision of the World Health Organization evokes the World Transhumanist Association. Transhumanists aspire to a civilization of superhappiness, superlongevity and superintelligence; but even an architecture of mind based on information-sensitive gradients of bliss cannot yield complete well-being. Post-Darwinian life will be sublime, but “complete” well-being is posthuman – more akin to Buddhist nirvana. So the aim of this talk is twofold. First, I shall explore the therapeutic interventions needed to underwrite the WHO conception of good health for everyone – or rather, a recognisable approximation of lifelong good health. What genes, allelic combinations and metabolic pathways must be targeted to deliver a biohappiness revolution: life based entirely on gradients of well-being? How can we devise a more civilized signalling system for human and nonhuman animal life than gradients of mental and physical pain? Secondly, how can genome reformists shift the Overton window of political discourse in favour of hedonic uplift? How can prospective parents worldwide – and the World Health Organization – be encouraged to embrace genome reform? For only germline engineering can fix the problem of suffering and create a happy biosphere for all sentient beings.
The End of Suffering – Genome Reform and the Future of Sentience – David Pearce
Now, a new algorithm developed by Brown University bioengineers could be an important step toward such adaptive DBS. The algorithm removes a key hurdle that makes it difficult for DBS systems to sense brain signals while simultaneously delivering stimulation.
“We know that there are electrical signals in the brain associated with disease states, and we’d like to be able to record those signals and use them to adjust neuromodulation therapy automatically,” said David Borton, an assistant professor of biomedical engineering at Brown and corresponding author of a study describing the algorithm. “The problem is that stimulation creates electrical artifacts that corrupt the signals we’re trying to record. So we’ve developed a means of identifying and removing those artifacts, so all that’s left is the signal of interest from the brain.”
Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine. The two researchers recently marked a major milestone in their effort to create an effective vaccine for the virus with the publishing of their paper “Structure-based design and antigenic validation of respiratory syncytial virus G immunogens” in the Journal of Virology.
For fifth-year Baskin Engineering student and the paper’s lead author Nuñez Castrejon, a bout of pneumonia that lingered for months when she was an undergraduate student sparked her interest in studying respiratory illnesses. For DuBois, watching her child go through a serious infection of RSV, which can cause severe respiratory infections in infants/children and the elderly, led her to study the disease.
“We have all of these wonderful childhood vaccines that have eliminated so much childhood disease, but there are still a lot of infectious diseases that are really tough on children, and RSV is one of those that causes hospitalizations in children,” DuBois said.
Immunomodulatory Biomaterials In Regenerative Medicine — Dr. Kara Spiller-Geisler, Ph.D., Drexel University School of Biomedical Engineering, Science and Health Systems.
Dr. Kara Spiller, PhD (https://drexel.edu/biomed/faculty/core/SpillerKara/) is Associate Professor in the Biomaterials and Regenerative Medicine Laboratory at Drexel University, in Philadelphia.
Dr. Spiller received her bachelor’s, master’s, and doctoral degrees in biomedical engineering from Drexel University where she conducted her doctoral research in the design of semi-degradable hydrogels for the repair of articular cartilage in the Biomaterials and Drug Delivery Laboratory at Drexel, and in the Shanghai Key Tissue Engineering Laboratory of Shanghai Jiao Tong University.
After completing her PhD, when she received the award for Most Outstanding Doctoral Graduate: Most Promise to Enhance Drexel’s Reputation, she conducted research in the design of scaffolds for bone tissue engineering as a Fulbright Fellow, in the Biomaterials, Biodegradables, and Biomimetics (the 3Bs) Research Group at the University of Minho in Guimaraes, Portugal. She also worked as a Postdoctoral Scientist at Columbia University.
Dr. Spiller is currently conducting research in the design of immuno-modulatory biomaterials, particularly for bone tissue engineering. Her research interests include cell-biomaterial interactions, biomaterial design, and international engineering education.
Circa 2015
Stanford bioengineer Manu Prakash and his students have developed a synchronous computer that operates using the unique physics of moving water droplets.
Computers and water typically don’t mix, but in Manu Prakash’s lab, the two are one and the same. Prakash, an assistant professor of bioengineering at Stanford, and his students have built a synchronous computer that operates using the unique physics of moving water droplets.
The computer is nearly a decade in the making, incubated from an idea that struck Prakash when he was a graduate student. The work combines his expertise in manipulating droplet fluid dynamics with a fundamental element of computer science – an operating clock.
The CRISPR gene-editing system is a powerful tool that could revolutionize medicine and other sciences, but unfortunately it has a tendency to make edits to the wrong sections of DNA. Now, researchers at the University of Texas at Austin have identified a previously unknown structure of the protein that drives these mistakes, and tweaked it to reduce the likelihood of off-target mutations by 4,000 times.
CRISPR tools use certain proteins, most often Cas9, to make precise edits to specific DNA sequences in living cells. This can involve cutting out problematic genes, such as those that cause disease, and/or slotting in beneficial ones. The problem is that sometimes the tool can make changes to the wrong parts, potentially triggering a range of other health issues.
And in the new study, the UT researchers discovered how some of these errors can happen. Usually, the Cas9 protein is hunting for a specific sequence of 20 letters in the DNA code, but if it finds one where 18 out of 20 match its target, it might make its edit anyway. To find out why this occurs, the team used cryo-electron microscopy to observe what Cas9 is doing when it interacts with a mismatched sequence.